FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992679346> ?p ?o ?g. }

• W1992679346 endingPage "284" @default.
• W1992679346 startingPage "283" @default.
• W1992679346 abstract "Dear Editor, We read with interest the article by Yi-Fu H. et al. [1] about the effectiveness of Lamivudine (LAM) prophylaxis in preventing hepatitis B viral (HBV) reactivation in Rituximab containing regimens (so called immunochemotheraphy, ICT) for lymphoma and would like to make a contribution to this emerging topic. All patients diagnosed with Non-Hodgkin Lymphoma (NHL) from January 2005 to March 2008, at our Institution, were screened for HBV serology: HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe. Patients were also tested for HCV antibodies (HIV-positive patients were not included): 18 out of 159 patients (11.3%) had serological signs of HBV exposure. 12 out of 159 (8.1%) patients were HCV-infected. Seven out of 18 HBV carriers were coinfected with HCV (38.8%). In 11 out of 18 patients (61%), HBsAg were negative [2], anti-HBc (nine patients), anti-HBs (one patient, no history of previous vaccination), anti-HBc/anti-HBe/anti-HBs (one patient) being the only positive markers of previous HBV exposure. Three patients were known to be affected by mild HBV chronic active hepatitis at the time of lymphoma diagnosis and were treated with LAM to contain the disease process before and after ICT. The remaining four inactive HBsAg carriers and the 11 HBsAg-negative/antiHBc-positive patients were started on LAM as a preemptive treatment to prevent possible disease reactivation [3]. Patients began treatment with LAM 100 mg/day po on average 3–4 weeks before embarking on chemotherapy, after signing informed consent. All 159 patients were given R-CHOP or R-CHOP-like regimens [4]. LAM treatment was extended to 18 months after that the new indications from the dedicated commission of the Italian Study of the Liver became widely available in 2007 [3]. During and after ICT discontinuation, patients were tested every 2 months for HBsAg, quantitative-HBV-DNA, ALT, and AST. Median follow-up time was 7 months (range 3–43). Five of the seven HBsAg-positive patients (71.4%) became HBV-DNA positive during follow-up at 25, 18, 18, 10, and 7 months after commencing LAM. In two patients, emergence of HBV-DNA positivity was associated with an increase of serum transaminases (up to five times the upper normal limit). In these five patients, AdefovirDipivoxyl, 10 mg/day po, was combined with LAM, resulting in a disappearance of HBV-DNA and regression of the biochemical signs of hepatitis. None of these patients had to discontinue ICT because of HBV reactivation. No liver-related deaths occurred. None of the HBcAbpositive, anti-HBs-positive/HBsAg-negative patients (potential silent carriers) developed HBV reactivation during the period of observation. No side effect related either to LAM or ADV was registered. Four out of seven of these patients are now undergoing new treatments because of lymphoma progression. The prevalence of HBV infection is high among patients diagnosed with NHL as compared to less than 2% of the Italian adult population [5]. Reactivation of HBV infection can present a serious threat to these patients and to the Ann Hematol (2009) 88:283–284 DOI 10.1007/s00277-008-0609-2" @default.
• W1992679346 created "2016-06-24" @default.
• W1992679346 creator A5010181678 @default.
• W1992679346 creator A5022734154 @default.
• W1992679346 creator A5023519590 @default.
• W1992679346 creator A5049004748 @default.
• W1992679346 creator A5053389629 @default.
• W1992679346 creator A5060066646 @default.
• W1992679346 creator A5070294061 @default.
• W1992679346 creator A5070384560 @default.
• W1992679346 creator A5070768830 @default.
• W1992679346 creator A5073940210 @default.
• W1992679346 date "2008-09-20" @default.
• W1992679346 modified "2023-09-23" @default.
• W1992679346 title "Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?" @default.
• W1992679346 cites W1967017906 @default.
• W1992679346 cites W1982202435 @default.
• W1992679346 cites W2015887202 @default.
• W1992679346 cites W2058015212 @default.
• W1992679346 cites W2110809164 @default.
• W1992679346 cites W2138477584 @default.
• W1992679346 cites W2163208122 @default.
• W1992679346 cites W2418107798 @default.
• W1992679346 doi "https://doi.org/10.1007/s00277-008-0609-2" @default.
• W1992679346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18807036" @default.
• W1992679346 hasPublicationYear "2008" @default.
• W1992679346 type Work @default.
• W1992679346 sameAs 1992679346 @default.
• W1992679346 citedByCount "2" @default.
• W1992679346 countsByYear W19926793462012 @default.
• W1992679346 crossrefType "journal-article" @default.
• W1992679346 hasAuthorship W1992679346A5010181678 @default.
• W1992679346 hasAuthorship W1992679346A5022734154 @default.
• W1992679346 hasAuthorship W1992679346A5023519590 @default.
• W1992679346 hasAuthorship W1992679346A5049004748 @default.
• W1992679346 hasAuthorship W1992679346A5053389629 @default.
• W1992679346 hasAuthorship W1992679346A5060066646 @default.
• W1992679346 hasAuthorship W1992679346A5070294061 @default.
• W1992679346 hasAuthorship W1992679346A5070384560 @default.
• W1992679346 hasAuthorship W1992679346A5070768830 @default.
• W1992679346 hasAuthorship W1992679346A5073940210 @default.
• W1992679346 hasBestOaLocation W19926793462 @default.
• W1992679346 hasConcept C121608353 @default.
• W1992679346 hasConcept C126322002 @default.
• W1992679346 hasConcept C159047783 @default.
• W1992679346 hasConcept C194409129 @default.
• W1992679346 hasConcept C2522874641 @default.
• W1992679346 hasConcept C2777869810 @default.
• W1992679346 hasConcept C2780593183 @default.
• W1992679346 hasConcept C2908731994 @default.
• W1992679346 hasConcept C71924100 @default.
• W1992679346 hasConcept C90924648 @default.
• W1992679346 hasConceptScore W1992679346C121608353 @default.
• W1992679346 hasConceptScore W1992679346C126322002 @default.
• W1992679346 hasConceptScore W1992679346C159047783 @default.
• W1992679346 hasConceptScore W1992679346C194409129 @default.
• W1992679346 hasConceptScore W1992679346C2522874641 @default.
• W1992679346 hasConceptScore W1992679346C2777869810 @default.
• W1992679346 hasConceptScore W1992679346C2780593183 @default.
• W1992679346 hasConceptScore W1992679346C2908731994 @default.
• W1992679346 hasConceptScore W1992679346C71924100 @default.
• W1992679346 hasConceptScore W1992679346C90924648 @default.
• W1992679346 hasIssue "3" @default.
• W1992679346 hasLocation W19926793461 @default.
• W1992679346 hasLocation W19926793462 @default.
• W1992679346 hasLocation W19926793463 @default.
• W1992679346 hasLocation W19926793464 @default.
• W1992679346 hasLocation W19926793465 @default.
• W1992679346 hasLocation W19926793466 @default.
• W1992679346 hasOpenAccess W1992679346 @default.
• W1992679346 hasPrimaryLocation W19926793461 @default.
• W1992679346 hasRelatedWork W1969842237 @default.
• W1992679346 hasRelatedWork W1974674628 @default.
• W1992679346 hasRelatedWork W1992679346 @default.
• W1992679346 hasRelatedWork W2046657202 @default.
• W1992679346 hasRelatedWork W2067469423 @default.
• W1992679346 hasRelatedWork W2143314226 @default.
• W1992679346 hasRelatedWork W2146713183 @default.
• W1992679346 hasRelatedWork W2359884894 @default.
• W1992679346 hasRelatedWork W2398300531 @default.
• W1992679346 hasRelatedWork W4237184734 @default.
• W1992679346 hasVolume "88" @default.
• W1992679346 isParatext "false" @default.
• W1992679346 isRetracted "false" @default.
• W1992679346 magId "1992679346" @default.
• W1992679346 workType "article" @default.